Ventiv Health to Provide Specialty Oncology Services to MDS Nordion
19 August 2004 - 2:55PM
PR Newswire (US)
Ventiv Health to Provide Specialty Oncology Services to MDS Nordion
Program to Focus on TheraSphere(R) Product for Primary
Hepatocellular Carcinoma SOMERSET, N.J., Aug. 19
/PRNewswire-FirstCall/ -- Ventiv Health, Inc. (NASDAQ:VTIV)
announced today its agreement with MDS Nordion to provide specialty
oncology account management representatives to market and sell
TheraSphere(R) in the United States. TheraSphere(R) is a
technologically advanced form of brachytherapy to treat
hepatocellular carcinoma. There are 9,000 cases of this type of
liver cancer currently in the U.S. Initially, Ventiv will provide
MDS Nordion with two full-time dedicated oncology account
specialists who will detail TheraSphere in the U.S. as well as one
full-time national business director. Ventiv will recruit, hire and
train the TheraSphere team and will develop program procedures,
customize processes and establish performance parameters.
"TheraSphere offers an alternative to chemotherapy in inoperable
cases of primary hepatocellular carcinoma, one of the most common
forms of liver cancer in the world," said Peter Pattison, MDS
Nordion's VP of Therapeutic Products. "Because of the science and
specialization involved in marketing TheraSphere to the physician
community, it was important to work with a specialized provider of
sales and marketing ideas and solutions. Ventiv is a perfect
partner for MDS Nordion in this capacity." Commenting on the
agreement, Terrell Herring, President and COO, Ventiv Pharma
Services said, "Given Ventiv's flexible structure and
specialization in many different areas, we were able to work with
MDS Nordion to provide the most comprehensive program for
TheraSphere, focusing on oncology and sourcing the best possible
sales representatives for this unique therapy." About
TheraSphere(R) MDS Nordion's TheraSphere(R), consisting of
yttrium-90 (Y-90) glass microspheres, is a technologically advanced
form of brachytherapy. TheraSphere(R) is available commercially in
the United States as a humanitarian device for use in radiation
treatments as a neoadjuvant to surgery or transplantation in
patients with unresectable hepatocellular carcinoma who can have
placement of appropriately positioned hepatic arterial catheters.
For more information, please visit http://www.therasphere.com/.
About Ventiv Health Ventiv Health, Inc. (NASDAQ:VTIV) is a leading
provider of sales, marketing, and compliance solutions to the
world's largest pharmaceutical companies as well as to emerging and
specialty pharmaceutical and biotech organizations. Ventiv has
established its leadership position within the industry based on a
long history of building and managing sales teams and providing
consultative planning and analytics services across multiple
therapeutic areas. The Ventiv delivery model is flexible and client
focused, enabling Ventiv to rapidly respond to changing client
needs and market conditions across the full spectrum of sales and
marketing support, with both integrated and independent programs.
These include: Sales and Marketing Teams (Ventiv Sales and
Marketing Teams(TM)), Planning and Analytics (Health Products
Research(R)), Recruitment (Ventiv Recruitment Services(TM)),
Professional Development and Training (Ventiv Professional
Development Group(TM)), Marketing Support (PROMOTECH), Data
Solutions (Total Data Solutions(TM)), Clinical Support (The
Therapeutics Institute(TM)), and Sample Accountability/Patient
Assistance Programs (The Franklin Group). Ventiv is a
multi-discipline company with a singular focus on providing
excellence in customized solutions to meet clients' sales and
marketing objectives. Ventiv's approximately 2,600 employees
support over forty client organizations. For more information on
Ventiv Health, visit http://www.ventiv.com/. About MDS Nordion MDS
Nordion, with headquarters in Ottawa, Ontario, is a global leader
specializing in radioisotopes, radiation, and related technologies
used to diagnose, prevent and treat disease. MDS Nordion is a
leader in development and commercialization of radiotherapeutics.
In addition to MDS Nordion's proprietary product TheraSphere, MDS
Nordion manufactures Bexxar(R) [I-131 tositumomab] for Corixa Corp.
and their distributor GlaxoSmithKline, as well as Yttrium-90
Chloride Sterile Solution for use with Zevalin [Y-90 ibritumomab
tiuxetan] for Biogen Idec Inc. MDS Nordion
(http://www.mds.nordion.com/) is part of MDS Inc.,
(TSE:MDSTSE:NYSE:TSE:MDZ), an international health and life
sciences company based in Canada. In many of its products and
services, MDS is among the largest and most respected companies in
the world. MDS fights disease. The company's 11,000 employees are
working together to advance global health through science,
technology and innovation. It does this by providing: laboratory
testing, imaging agents for nuclear medicine testing, sterilization
systems for medical and consumer products, research services to
speed the discovery and development of new drugs, therapy systems
for planning and delivery of cancer treatment, analytical
instruments to assist in the development of new drugs, and
medical/surgical supplies. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv
Health's performance to differ materially. Such risks include,
without limitation: changes in trends in the pharmaceutical
industry or in pharmaceutical outsourcing; our ability to compete
successfully with other services in the market; our ability to
maintain large client contracts or to enter into new contracts;
uncertainties related to future incentive payments; and, our
ability to operate successfully in new lines of business. Readers
of this press release are referred to documents filed from time to
time by Ventiv Health Inc. with the Securities and Exchange
Commission for further discussion of these and other factors.
DATASOURCE: Ventiv Health, Inc. CONTACT: John Emery, CFO of Ventiv
Health, Inc., +1-732-537-4804, ; or Felicia Vonella of Lazar
Partners Ltd., +1-212-867-1762, , for Ventiv Health, Inc. Web site:
http://www.ventiv.com/ http://www.mds.nordion.com/
http://www.therasphere.com/
Copyright